| 0.05 0 (0%) | 01-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Amyris, Inc. is a synthetic biotechnology enterprise with global operations in the clean health, beauty, and flavors and fragrance sectors, covering Europe, North America, Asia, and South America. The company produces and sells a variety of consumer goods, including clean beauty, personal care, and health and wellness products, as well as specialized ingredients supplied to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care industries. Its product offerings are marketed under brand names such as Biossance, Pipette, Purecane, Terasana, Costa Brazil, OLIKA, Rose Inc., and JVN. Amyris also engages in a collaborative agreement with the Infectious Disease Research Institute for the advancement of a COVID-19 vaccine. Founded in 2003 and based in Emeryville, California, the company operated as Amyris Biotechnologies, Inc. until it adopted its current name, Amyris, Inc., in June 2010.
Thu, 10 Aug 2023
Biotech Company Amyris Files for Bankruptcy - investopedia.com
Wed, 09 Aug 2023
AMYRIS ANNOUNCES OPERATIONAL AND FINANCIAL RESTRUCTURING TO ADVANCE STRATEGIC TRANSFORMATION - PR Newswire
Fri, 19 May 2023
AMYRIS COMPLETES LICENSE FOR SUPPLY OF SUSTAINABLE SQUALENE - PR Newswire
Mon, 24 Oct 2022
AMYRIS SUCCESSFULLY LAUNCHES TWO NEW CONSUMER BRANDS - PR Newswire
Thu, 23 Jun 2022
AMYRIS BARRA BONITA FERMENTATION PLANT BEGINS INDUSTRIAL PRODUCTION - PR Newswire
Fri, 17 Jun 2022
Amyris Inc. (AMRS) Share Price Today | Amyris (AMRS) Live NSE/BSE - Value Research
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Basic Materials
|
|
|
Industry:
Chemicals - Specialty
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|